These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 8707091)

  • 1. Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors.
    Giardiello FM; Offerhaus JA; Tersmette AC; Hylind LM; Krush AJ; Brensinger JD; Booker SV; Hamilton SR
    Gut; 1996 Apr; 38(4):578-81. PubMed ID: 8707091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis.
    Hisamuddin IM; Wehbi MA; Schmotzer B; Easley KA; Hylind LM; Giardiello FM; Yang VW
    Cancer Epidemiol Biomarkers Prev; 2005 Oct; 14(10):2366-9. PubMed ID: 16214918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of sulindac on sporadic colorectal adenomatous polyps.
    Matsuhashi N; Nakajima A; Fukushima Y; Yazaki Y; Oka T
    Gut; 1997 Mar; 40(3):344-9. PubMed ID: 9135523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac.
    Keller JJ; Offerhaus GJ; Polak M; Goodman SN; Zahurak ML; Hylind LM; Hamilton SR; Giardiello FM
    Gut; 1999 Dec; 45(6):822-8. PubMed ID: 10562579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment with sulindac in familial adenomatous polyposis: is there an actual efficacy in prevention of rectal cancer?
    Tonelli F; Valanzano R; Messerini L; Ficari F
    J Surg Oncol; 2000 May; 74(1):15-20. PubMed ID: 10861602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue prostanoids as biomarkers for chemoprevention of colorectal neoplasia: correlation between prostanoid synthesis and clinical response in familial adenomatous polyposis.
    Yang VW; Geiman DE; Hubbard WC; Spannhake EW; Hylind LM; Hamilton SR; Giardiello FM
    Prostaglandins Other Lipid Mediat; 2000 Jan; 60(1-3):83-96. PubMed ID: 10680778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of suindac in the treatment of familial adenomatous polyposis coli].
    Landauer S; Halimi C; Caulin C; Bergmann JF
    Therapie; 1999; 54(6):675-82. PubMed ID: 10709439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study.
    Cruz-Correa M; Hylind LM; Romans KE; Booker SV; Giardiello FM
    Gastroenterology; 2002 Mar; 122(3):641-5. PubMed ID: 11874996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months.
    Winde G; Schmid KW; Schlegel W; Fischer R; Osswald H; Bünte H
    Dis Colon Rectum; 1995 Aug; 38(8):813-30. PubMed ID: 7634976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary chemoprevention of familial adenomatous polyposis with sulindac.
    Giardiello FM; Yang VW; Hylind LM; Krush AJ; Petersen GM; Trimbath JD; Piantadosi S; Garrett E; Geiman DE; Hubbard W; Offerhaus GJ; Hamilton SR
    N Engl J Med; 2002 Apr; 346(14):1054-9. PubMed ID: 11932472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
    Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
    BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the non-steroidal anti-inflammatory drug sulindac on colorectal adenomas of uncolectomized familial adenomatous polyposis.
    Matsumoto T; Nakamura S; Esaki M; Yao T; Iida M
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):251-7. PubMed ID: 16460482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
    Bowen CM; Walter L; Borras E; Wu W; Ozcan Z; Chang K; Bommi PV; Taggart MW; Thirumurthi S; Lynch PM; Reyes-Uribe L; Scheet PA; Sinha KM; Vilar E
    Cancer Prev Res (Phila); 2021 Sep; 14(9):851-862. PubMed ID: 34266857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rectal cancer after sulindac therapy for a sporadic adenomatous colonic polyp.
    Matsuhashi N; Nakajima A; Shinohara K; Oka T; Yazaki Y
    Am J Gastroenterol; 1998 Nov; 93(11):2261-6. PubMed ID: 9820411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
    Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fate of the rectal stump after colectomy and ileorectal anastomosis for familial adenomatous polyposis.
    Heiskanen I; Järvinen HJ
    Int J Colorectal Dis; 1997; 12(1):9-13. PubMed ID: 9112143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment with sulindac of adenomatous polyps in familial polyposis].
    Cerdán FJ; Torres-Melero J; Martínez S; Gutiérrez del Olmo A; Balibrea JL
    Rev Esp Enferm Dig; 1995 Aug; 87(8):574-6. PubMed ID: 7577106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulindac in familial adenomatous polyposis: evaluation by nuclear morphometry.
    Fernández-López F; Conde-Freire R; Cadarso-Suárez C; García-Iglesias J; Puente-Domínguez JL; Potel-Lesquereux J
    Eur J Surg; 2001 May; 167(5):375-81. PubMed ID: 11419555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
    Samadder NJ; Kuwada SK; Boucher KM; Byrne K; Kanth P; Samowitz W; Jones D; Tavtigian SV; Westover M; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Burt RW; Neklason DW
    JAMA Oncol; 2018 May; 4(5):671-677. PubMed ID: 29423501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis.
    Guldenschuh I; Hurlimann R; Muller A; Ammann R; Mullhaupt B; Dobbie Z; Zala GF; Flury R; Seelentag W; Roth J; Meyenberger C; Fried M; Hoppeler T; Spigelman AD; Scott RJ
    Dis Colon Rectum; 2001 Aug; 44(8):1090-7; discussion 1097-9. PubMed ID: 11535846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.